Last reviewed · How we verify

NCT05996198

Exoskeletal Support in Stroke

Completed NA Results posted Last updated 1 April 2025
What this trial tests

NA trial testing Oculus Rift headset in Stroke in 19 participants. Completed in 29 April 2024.

Timeline
3 January 2024
Primary endpoint
29 April 2024
29 April 2024

Quick facts

Lead sponsorNYU Langone Health
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment19
Start date3 January 2024
Primary completion29 April 2024
Estimated completion29 April 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

NYU Langone Health — full company profile →

Who can join

18 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Relative Contribution (RC) Primary · End of VR Task (Day 1 - session lasts approx. 2 hours)

Relative Contribution (RC) is a measure of the relative displacement between the hands during a bimanual reaching task. Displacement of both hands was measured using 3D motion capture using the Oculus Rift VR system. RC is calculated as the displacement of the more-impaired hand divided by the sum of displacements of both hands, multiplied by 100.

GroupValue95% CI
Patients With History of Stroke-0.74± 1.94
Healthy Controls-0.25± 1.65
Muscle Contribution (MC) Primary · Baseline, End of VR Task (Day 1 - session lasts approx. 2 hours)

Muscle Contribution (MC) is a measure of the relative muscle activity between the arms during a bimanual reaching task. Muscle activity was measured using electromyography (EMG); the root-mean-square (RMS) of the EMG timeseries signal in the anterior deltoid. MC in the anterior deltoid was calculated as the RMS in the more-impaired anterior deltoid divided by the sum of RMS values in both anterior deltoids, multiplied by 100. For example, an MC (deltoid) value of 50% indicates that the muscle activity in both anterior deltoids was the same while reaching; an MC value less than 50% indicates th

GroupValue95% CI
Patients With History of Stroke-0.68± 2.86
Healthy Controls-4.35± 11.58
Corticospinal Tract (CST) Lesion Load Secondary · Baseline

Measured via MRI; lesion load is expressed as percentage of the entire CST.

GroupValue95% CI
Patients With History of Stroke5.71± 6.6

Sponsor's own description

This interventional study will measure motor performance, including 3D movement analysis and muscle activity, in response to exoskeleton assistance. The cohort design will compare stroke patients to healthy controls. Data collection will be conducted in a single, 2-hour session. Investigators will also access stroke patients' brain MRIs that were obtained as standard of care during acute admission for stroke.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other NYU Langone Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05996198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing